Treatment of Varicose Veins/Venous Insufficiency

MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Treatment of Varicose Veins/Venous Insufficiency Number 7.01.519 Effective Date January 12, 2016 Revision Date(s) 01/12/16; 11/10/15; 06/09/15; 05/12/15; 02/10/15; 06/09/14; 10/14/13; 06/14/13; 04/08/13; 12/11/12 Replaces 7.01.55, 7.01.76, 7.01.515, 7.01.124 Policy [TOP] Greater or Lesser (small) Saphenous Veins Treatment of the greater or lesser (small) saphenous veins by surgery (ligation and stripping), endovenous radiofrequency, laser ablation or microfoam sclerotherapy (e.g. Varithena) may be considered medically necessary for symptomatic varicose veins/venous insufficiency when the following criteria have been met: AND There is moderate to severe (greater than 0.5 second) saphenous reflux documented on venous studies and CEAP [Clinical-Etiology-Anatomy-Pathophysiology] class C2 or greater (see Definition of Terms); There is documentation of one or more of the following 4 indications: o Ulceration secondary to venous stasis; OR o Recurrent superficial thrombophlebitis; OR o o Hemorrhage or recurrent bleeding episodes from a ruptured superficial varicosity; OR Persistent pain, swelling, itching, burning, or other symptoms are associated with saphenous reflux, AND o These symptoms significantly interfere with activities of daily living, AND o Conservative management, including compression therapy for at least 3 months, has not improved the symptoms. Note: If compression therapy is successful, it should be continued for as long as it is working. Failure of conservative therapy is defined as pain, swelling, itching, burning, or other symptoms associated with vein reflux, despite conservative therapy, severe enough to require daily pain medicines and causing inability to manage daily activities at home or at work. Treatment of greater or lesser (small) saphenous veins by surgery, endovenous radiofrequency, laser ablation, or microfoam sclerotherapy that does not meet the criteria described above is considered not medically necessary. Treatment of the greater or lesser (small) saphenous veins using techniques not noted above is considered investigational, including, but not limited to: Cyanoacrylate adhesive/cyanoacrylate embolization (CAE) (e.g. VenaSeal System) Endovenous cryoablation Endovenous mechanochemical ablation (MCA) (e.g. MOCA ClariVein) Stab avulsion Stab/Hook/Micro-phlebectomy Transilluminated powered phlebectomy (TIPP) (e.g. TRIVEX System)

Accessory Saphenous Veins Treatment of accessory saphenous veins by surgery (ligation and stripping), endovenous radiofrequency, laser ablation or microfoam sclerotherapy may be considered medically necessary for symptomatic varicose veins/venous insufficiency when the following criteria have been met: The greater or lesser (small) saphenous veins have been previously eliminated (at least 3 months) when the greater or lesser (small) saphenous veins had reflux; OR There is no reflux documented in both the greater and lesser (small) saphenous veins; AND AND There is moderate to severe (greater than 0.5 second ) accessory saphenous reflux documented on venous studies; There is documentation of one or more of the following 4 indications: o Ulceration secondary to venous stasis; OR o Recurrent superficial thrombophlebitis; OR o o Hemorrhage or recurrent bleeding episodes from a ruptured superficial varicosity; OR Persistent pain, swelling, itching, burning, or other symptoms are associated with saphenous reflux, AND These symptoms significantly interfere with activities of daily living, AND Conservative management, including compression therapy for at least 3 months, has not improved these symptoms. Note: If compression therapy is successful, it should be continued for as long as it is working. Failure of conservative therapy is defined as pain, swelling, itching, burning, or other symptoms associated with vein reflux, despite conservative therapy, severe enough to require daily pain medicines and causing inability to manage daily activities at home or at work. Treatment of accessory saphenous veins by surgery, endovenous radiofrequency, laser ablation, or microfoam sclerotherapy that does not meet the criteria described above is considered not medically necessary. Treatment of the accessory saphenous veins using techniques not noted above is considered investigational, including, but not limited to: Cyanoacrylate adhesive/cyanoacrylate embolization (CAE) (e.g. VenaSeal System) Endovenous cryoablation Endovenous mechanochemical ablation (MCA) (e.g. MOCA ClariVein) Stab avulsion Stab/Hook/Micro-phlebectomy Transilluminated powered phlebectomy (TIPP) (e.g. TRIVEX System) Symptomatic Varicose Tributaries The following treatments are considered medically necessary as a component of the treatment of symptomatic varicose tributaries when performed concurrently with or within 10 days of treatment (surgical, radiofrequency or laser) of the saphenous veins (none of these techniques has been shown to be superior to another): Sclerotherapy Stab avulsion Stab/Hook/Micro-phlebectomy Transilluminated powered phlebectomy (TIPP) (e.g. TRIVEX System) When stab avulsion, hook phlebectomy, sclerotherapy, or transilluminated powered phlebectomy (TIPP) is requested more than 10 days following a prior surgical, radiofrequency or laser treatment, it may be considered medically necessary when there is documentation of one or more of the following 4 indications: Ulceration secondary to venous stasis; OR Recurrent superficial thrombophlebitis; OR Hemorrhage or recurrent bleeding episodes from a ruptured superficial varicosity; OR Persistent pain, swelling, itching, burning, or other symptoms are associated with saphenous reflux, AND o These symptoms significantly interfere with activities of daily living, AND o Conservative management, including compression therapy for at least 3 months, has not

improved these symptoms. Note: If compression therapy is successful, it should be continued for as long as it is working. Failure of conservative therapy is defined as pain, swelling, itching, burning, or other symptoms associated with vein reflux, despite conservative therapy, severe enough to require daily pain medicines and causing inability to manage daily activities at home or at work. Treatment of symptomatic varicose tributaries when performed either at the same time or following prior treatment of saphenous veins using any other techniques than noted above is considered investigational, including, but not limited to: Cyanoacrylate adhesive/cyanoacrylate embolization (CAE) (e.g. VenaSeal System) Endovenous cryoablation Endovenous mechanochemical ablation (MCA) (e.g. MOCA ClariVein) Endovenous radiofrequency or laser ablation Perforator Veins Surgical ligation (including subfascial endoscopic perforator surgery) or endovenous radiofrequency or laser ablation of incompetent perforator veins may be considered medically necessary as a treatment of leg ulcers associated with chronic venous insufficiency when ALL of the following conditions have been met: There is demonstrated perforator reflux; AND The superficial saphenous veins (greater, lesser, or accessory saphenous and symptomatic varicose tributaries) have been previously eliminated; AND Ulcers have not resolved following combined superficial vein treatment and compression therapy for at least 3 months; AND The venous insufficiency is not secondary to deep venous thromboembolism. Ligation or ablation of incompetent perforator veins performed concurrently with superficial venous surgery is not medically necessary. Treatment of incompetent perforator veins using any other techniques than noted above is considered investigational, including, but not limited to: Cyanoacrylate adhesive/cyanoacrylate embolization (CAE) (e.g. VenaSeal System) Endovenous mechanochemical ablation (MCA) (e.g. MOCA ClariVein) Sclerotherapy Stab avulsion Stab/Hook/Micro-phlebectomy Transilluminated powered phlebectomy (TIPP) (e.g. TRIVEX System) Telangiectasia Treatment, by any method, of small telangiectasia such as spider veins (1mm or less), superficial reticular veins (1-2 mm), angiomata, and hemangiomata is considered cosmetic. Related Policies 10.01.514 Cosmetic and Reconstructive Services [TOP] Policy Guidelines [TOP]

Ultrasound Guidance It should be noted that the bulk of the literature discussing the role of ultrasound guidance refers to sclerotherapy of the saphenous vein, as opposed to the varicose tributaries. When ultrasound guidance is used to guide sclerotherapy of the varicose tributaries, it would be considered either not medically necessary or incidental to the injection procedure. Documentation Requirements Review of this technology requires the provider to specifically indicate in the clinical notes submitted: The CPT codes for the procedures being requested AND The name of the vein to be treated with each CPT code. Coding CPT Procedure Name Notes 37799 Mechanochemical ablation Endo-Mechanical/ Endo-Chemical ablation (MCA) (See Coding section for individual code descriptions) 37799 36475 36476 36468 36471 37765 37766 Microfoam sclerotherapy (See Coding section for individual code description) Sclerotherapy Stab avulsion Stab/hook/micro-phlebectomy (See Coding section for individual code description) 37799 Transilluminated powered phlebectomy (TIPP) (See Coding section for individual code descriptions) 76942 Ultrasonic guidance for needle placement (for sclerotherapy) (See Coding section for individual code descriptions) Additional codes and descriptions can be found at the end of this policy. There is no specific code for the procedure (e.g. MOCA ClariVein). Procedures may be billed with the unlisted vascular surgery code. There is no specific code for the procedure (e.g. Varithena). Procedures may be billed the unlisted vascular surgery code. (See sclerotherapy in this table) Note: Use of CPT codes 36475-36476 is incorrect as this procedure is not ablation therapy. Procedures should be billed with the appropriate CPT codes. Note: These codes might also be used incorrectly for microfoam sclerotherapy. Procedures should be billed with the appropriate CPT codes. There are no specific codes for the procedure (e.g. TRIVEX System). Procedures may be billed with the unlisted vascular surgery code. When ultrasound guidance is used to guide sclerotherapy of the varicose tributaries, it would be considered either not medically necessary or incidental to the injection procedure. Definition of Terms Accessory saphenous veins Travel in parallel with the greater and lesser saphenous veins and are generally 2 to 2.5 mm in their normal state. CEAP [Clinical-Etiology-Anatomy-Pathophysiology] classification Considers the clinical, etiologic, anatomic, and pathologic (CEAP) characteristics of venous insufficiency. See table below. Class Clinical Classification C0 No visible or palpable signs of venous disease C1 Telangiectasies or reticular veins C2 Varicose veins C3 Edema C4a Pigmentation and eczema C4b Lipodermatosclerosis and atrophie blanche C5 Healed venous ulcer C6 Active venous ulcer S Symptoms including ache, pain, tightness, skin irritation, heaviness, muscle cramps, and other complaints attributable to venous dysfunction A Asymptomatic Greater/long saphenous vein: Superficial vein running the entire length of the leg and is generally 3 mm in its normal state. A typical GSV contains an average of 7 valves throughout its entire length, and it is the most

common superficial vein to develop venous reflux. Lesser (small)/short saphenous veins: Superficial vein of the calf and is generally 2.5 mm in its normal state. The small saphenous vein originates at the back of the ankle near the outer malleous bone, and usually runs up the back of the lower leg to the popliteal vein behind the knee. Moderate to severe reflux: In current practice, most vascular laboratories consider the presence of venous flow reversal for greater than 0.5 second with proximal compression, Valsalva maneuver, or distal compression and release to represent pathologic reflux. Perforator veins: These connect superficial veins to deep veins. They contain one-way valves to direct the blood from the superficial system to the deep system and are generally less than 3mm in their normal state. Stab avulsion: This technique is also known as stab/hook phlebectomy. Stab avulsion results in removal of the varicose veins through incisions that are 2-3 mm in length. The veins are hooked with a tiny hook-like instrument and pulled out. The wounds are closed with tapes, not sutures, and the leg is wrapped in elastic compression support. Once healed, the incision sites are almost invisible. Telangiectasia/spider veins: Very small ( 1 mm in diameter) thread veins found commonly just under the surface of the skin, usually not distorting skin or surrounding tissues. Tributary veins: Veins that empty into a larger vein Description [TOP] A variety of treatment modalities are available to treat varicose veins/venous insufficiency, including surgical approaches, thermal ablation, and sclerotherapy. The application of each of these treatment options is influenced by the severity of the symptoms, type of vein, source of venous reflux, and the use of other (prior or concurrent) treatments. Based on the available evidence, clinical input and clinical practice guidelines, the use of endovenous radiofrequency, laser ablation, and microfoam sclerotherapy are considered to improve outcomes when used in the saphenous veins. For treatment of saphenous tributaries at the same time or following treatment of the saphenous vein, stab avulsion, hook phlebectomy, sclerotherapy, or transilluminated powered phlebectomy improve outcomes Background The venous system of the lower extremities consists of the superficial veins (this includes the greater and lesser saphenous and accessory, or duplicate, veins that travel in parallel with the greater and lesser saphenous veins), the deep system (popliteal and femoral veins), and perforator veins that cross through the fascia and connect the deep and superficial systems. One-way valves are present within all veins to direct the return of blood up the lower limb. Because venous pressure in the deep system is generally greater than that of the superficial system, valve incompetence at any level may lead to backflow (venous reflux) with pooling of blood in superficial veins. Varicose veins with visible varicosities may be the only sign of venous reflux, although itching, heaviness, tension, and pain may also occur. Chronic venous insufficiency secondary to venous reflux can lead to thrombophlebitis, leg ulcerations, and hemorrhage. The CEAP classification considers the clinical, etiologic, anatomic, and pathologic (CEAP) characteristics of venous insufficiency, ranging from class 0 (no visible sign of disease) to class 6 (active ulceration). Treatment of venous reflux/venous insufficiency is aimed at reducing abnormal pressure transmission from the deep to the superficial veins. Conservative medical treatment consists of elevation of the extremities, graded compression, and wound care when indicated. Conventional surgical treatment consists of identifying and correcting the site of reflux by ligation of the incompetent junction followed by stripping of the vein to redirect venous flow through veins with intact valves. While most venous reflux is secondary to incompetent valves at the saphenofemoral or saphenopopliteal junctions, reflux may also occur at incompetent valves in the perforator veins

or in the deep venous system. The competence of any single valve is not static and may be pressure-dependent. For example, accessory saphenous veins may have independent saphenofemoral or saphenopopliteal junctions that become incompetent when the greater or lesser saphenous veins are eliminated and blood flow is diverted through the accessory veins. Saphenous Veins and Tributaries Saphenous veins include the greater and lesser saphenous and accessory saphenous veins that travel in parallel with the greater or lesser (small) saphenous veins. Tributaries are veins that empty into a larger vein. Treatment of venous reflux typically includes the following: Identification by preoperative Doppler ultrasonography of the valvular incompetence Control of the most proximal point of reflux, traditionally by suture ligation of the incompetent saphenofemoral or saphenopopliteal junction Removal of the superficial vein from circulation, for example by stripping of the greater and/or lesser saphenous veins Removal of varicose tributaries (at the time of the initial treatment or subsequently) by stab avulsion (phlebectomy) or injection sclerotherapy. Minimally invasive alternatives to ligation and stripping have been investigated. These include sclerotherapy, transilluminated-powered phlebotomy, and thermal ablation using cryotherapy, high frequency radiowaves (200 300 khz), or laser energy. Sclerotherapy The objective of sclerotherapy is to destroy the endothelium of the target vessel by injecting an irritant solution (either a detergent, osmotic solution, or chemical irritant), ultimately resulting in the occlusion of the vessel. The success of the treatment depends on accurate injection of the vessel, an adequate injectate volume and concentration of sclerosant, and compression. Historically, larger veins and very tortuous veins were not considered to be good candidates for sclerotherapy due to technical limitations. Technical improvements in sclerotherapy have included the routine use of Duplex ultrasound to target refluxing vessels, luminal compression of the vein with anesthetics, and a foam/sclerosant injectate in place of liquid sclerosant. Foam sclerosants are commonly produced by forcibly mixing a gas (e.g., air or carbon dioxide) with a liquid sclerosant (e.g., polidocanol or sodium tetradecyl sulfate). The foam is produced at the time of treatment. Varithena (previously known as Varisolve, BTG PLC, London) is a proprietary microfoam sclerosant that is dispersed from a canister with a controlled density and more consistent bubble size. Endovenous Mechanochemical Ablation (MCA) Endovenous mechanochemical ablation (MOCA ) utilizes both sclerotherapy and mechanical damage to the lumen. Following ultrasound imaging, a disposable catheter with a motor drive is inserted into the distal end of the target vein and advanced to the saphenofemoral junction. As the catheter is pulled back, a wire rotates at 3500 rpm within the lumen of the vein, abrading the lumen. At the same time, a liquid sclerosant (sodium tetradecyl sulfate) is infused near the rotating wire. It is proposed that mechanical ablation allows for better efficacy of the sclerosant, and results in less pain and risk of nerve injury without need for the tumescent anesthesia used with thermal endovenous ablation techniques (radiofrequency ablation [RFA] and endovenous laser treatment [EVLT]). Thermal Ablation Radiofrequency (RFA) ablation is performed by means of a specially designed catheter inserted through a small incision in the distal medial thigh to within 1 2 cm of the saphenofemoral junction. The catheter is slowly withdrawn, closing the vein. Laser ablation is performed similarly; a laser fiber is introduced into the greater saphenous vein under ultrasound guidance; the laser is activated and slowly removed along the course of the saphenous vein. Cryoablation uses extreme cold to cause injury to the vessel. The objective of endovenous techniques is to cause injury to the vessel, causing retraction and subsequent fibrotic occlusion of the vein. Technical developments since thermal ablation procedures were initially introduced include the use of perivenous tumescent anesthesia, which allows successful treatment of veins larger than 12 mm in diameter and helps to protect adjacent tissue from thermal damage during treatment of the lesser saphenous vein. Cyanoacrylate Adhesive for Embolization (CAE)

Cyanoacrylate adhesive is a clear, free-flowing liquid that polymerizes in the vessel via an anionic mechanism (i.e., polymerizes into a solid material on contact with body fluids or tissue). The adhesive is gradually injected along the length of the vein in conjunction with ultrasound and manual compression. The acute coaptation halts blood flow through the vein until the implanted adhesive becomes fibrotically encapsulated and establishes chronic occlusion of the treated vein. Cyanoacrylate glue has been used as a surgical adhesive and sealant for a variety of indications, including gastrointestinal bleeding, embolization of brain arteriovenous malformations, and to seal surgical incisions or other skin wounds. Transilluminated Powered Phlebectomy (TIPP) Transilluminated powered phlebectomy (TIPP) is an alternative to stab avulsion or hook phlebectomy. This procedure uses 2 instruments: an illuminator which also provides irrigation, and a resector, which has an oscillating tip and can perform suction. Following removal of the saphenous vein, the illuminator is introduced via a small incision in the skin and tumescence solution (anesthetic and epinephrine) is infiltrated along the course of the varicosity. The resector is then inserted under the skin from the opposite direction, and the oscillating tip is placed directly beneath the illuminated veins to fragment and loosen the veins from the supporting tissue. Irrigation from the illuminator is used to clear the vein fragments and blood through aspiration and additional drainage holes. The illuminator and resector tips may then be repositioned, thereby reducing the number of incisions needed when compared with stab avulsion or hook phlebectomy. It has been proposed that TIPP might result in decreased operative time, decreased complications such as bruising, and faster recovery compared to the established procedures. Treatment of Perforator Veins Perforator veins cross through the fascia and connect the deep and superficial venous systems. Incompetent perforating veins were originally addressed with an open surgical procedure, called the Linton procedure, which involved a long medial calf incision to expose all posterior, medial, and paramedial perforators. While this procedure was associated with healing of ulcers, it was largely abandoned due to a high incidence of wound complications. The Linton procedure was subsequently modified by using a series of perpendicular skin flaps instead of a longitudinal skin flap to provide access to incompetent perforator veins in the lower part of the leg. The modified Linton procedure may occasionally be used for the closure of incompetent perforator veins that cannot be reached by less invasive procedures. Subfascial endoscopic perforator surgery is a less-invasive surgical procedure for treatment of incompetent perforators and has been reported since the mid-1980s. Guided by Duplex ultrasound scanning, small incisions are made in the skin, and the perforating veins are clipped or divided by endoscopic scissors. The operation can be performed as an outpatient procedure. Endovenous ablation of incompetent perforator veins with sclerotherapy and RFA has also been reported. Other Deep vein valve replacement is being investigated. Outcomes of interest for venous interventions include healing and recurrence, recannulation of the vein, and neovascularization. Recannulation (recanalization) is the restoration of the lumen of a vein after it has been occluded; this occurs more frequently following treatment with endovenous techniques. Neovascularization is the proliferation of new blood vessels in tissue and occurs more frequently following vein stripping. Direct comparisons of durability for endovenous and surgical procedures are complicated by these different mechanisms of recurrence. Relevant safety outcomes include the incidence of paresthesia, thermal skin injury, thrombus formation, thrombophlebitis, wound infection, and transient neurologic effects. Regulatory Status In 2015, the VenaSeal Closure System (Sapheon, a part of Medtronic) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process for the permanent closure of clinically significant venous reflux through endovascular embolization with coaptation. The VenaSeal Closure System seals the vein using a cyanoacrylate adhesive agent. FDA product code: PJQ. In 2013, Varithena (formerly known as Varisolve (BTG PLC, London) is a sclerosant microfoam made with a proprietary gas mix. It was approved by the FDA in 2013 under a new drug application (NDA) for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein system above and below the knee.

The following devices have received specific U.S. Food and Drug Administration (FDA) marketing clearance for the endovenous treatment of superficial vein reflux: In 1999, the VNUS Closure system (a radiofrequency device) received FDA clearance through the 510(k) process for "endovascular coagulation of blood vessels in patients with superficial vein reflux." The VNUS RFS and RFSFlex devices received FDA clearance in 2005 for use in vessel and tissue coagulation including: treatment of incompetent (i.e., refluxing) perforator and tributary veins. The modified VNUS ClosureFAST Intravascular Catheter received FDA clearance through the 510(k) process in 2008. FDA product code: GEI. In 2002, the Diomed 810 nm surgical laser and EVLT (endovenous laser therapy) procedure kit received FDA clearance through the 510(k) process, " for use in the endovascular coagulation of the greater saphenous vein of the thigh in patients with superficial vein reflux." FDA product code: GEX. In 2005 a modified Erbe Erbokryo cryosurgical unit (Erbe USA) received FDA clearance for marketing. A variety of clinical indications are listed, including cryostripping of varicose veins of the lower limbs. FDA product code: GEH. In October 2003 the Trivex system received FDA clearance through the 510(k) process. The manufacturer, LeMaitre Vascular, describes it as a transilluminated powered phlebectomy system (TIPP). According to the label, the intended use is for ambulatory phlebectomy procedures for the resection and ablation of varicose veins. FDA product code: DNQ. In 2008 The ClariVein Infusion Catheter (Vascular Insights) received marketing clearance through the 510(k) process (K071468). It is used for mechanochemical ablation. Predicate devices were listed as the Trellis Infusion System (K013635) and the Slip-Cath Infusion Catheter (K882796). The system includes an infusion catheter, motor drive, stopcock and syringe and is intended for the infusion of physician-specified agents in the peripheral vasculature. FDA product code: KRA. Scope [TOP] Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage. Benefit Application N/A [TOP] Rationale [TOP] The most recent literature update using the PubMed/MEDLINE database was performed through July 7, 2015. Following is a summary of key studies to date. Treatment of Saphenous Reflux Compression Therapy A 2009 Cochrane review on compression for venous leg ulcers included a total of 39 randomized controlled trials (RCTs), with 47 different comparisons. (1) The review was updated in 2012, and included 48 RCTs with 59 different comparisons. (2) Most of the RCTs were small. Objective measures of healing were the time to complete healing, the proportion of ulcers healed within the trial period (typically 12 weeks), the change in ulcer size, and the rate of change in ulcer size. Evidence from 8 trials indicated that venous ulcers healed more rapidly with

compression than without. Findings suggested that multicomponent systems (bandages or stockings) were more effective than single-component compression. In addition, multicomponent systems containing an elastic bandage appeared more effective than those composed mainly of inelastic constituents. Although these meta-analyses did not include time to healing, studies included in the review reported that the mean time to ulcer healing was approximately 2 months, while the median time to healing in other reports was 3 to 5 months. A Cochrane review on compression stockings for the initial treatment of varicose veins in patients without venous ulceration was published in 2011. (3) Included in the review were 7 studies involving 356 participants with varicose veins without healed or active venous ulceration (CEAP [clinical, etiology, anatomy, pathophysiology] classification C2 to C4). Six of the studies compared different types or pressures of stockings. Subjectively, participants symptoms improved, but results were not compared with a control arm. Due primarily to inadequate reporting, the methodologic quality of the included trials was unclear. Meta-analyses were not performed due to inadequate reporting and suspected heterogeneity. The authors concluded that there is insufficient high-quality evidence to determine whether or not compression stockings are effective as the sole and initial treatment of varicose veins in patients without venous ulceration, or whether any type of stocking is superior to any other type. Ligation and Stripping Systematic literature reviews published in 2008 indicate a similar healing rate of venous ulcers with superficial vein surgery and conservative compression treatments but a reduction in ulcer recurrence rate with surgery. (4, 5) In general, recurrence rates after ligation and stripping are estimated at around 20%. Jones et al reported on the results of a study that randomized 100 patients with varicose veins to undergo either ligation alone or ligation in conjunction with stripping. (6) At 1 year, reflux was detected in 9% of patients, rising to 26% at 2 years. Rutgers and Kitslaar reported on the results of a trial that randomized 181 limbs to undergo either ligation and stripping or ligation combined with sclerotherapy. (7) At 2 years, Doppler ultrasound demonstrated reflux in approximately 10% of patients after ligation and stripping, increasing to 15% at 3 years. Comparison of Endovenous Ablation and Sclerotherapy with Ligation and Stripping An updated Cochrane review from 2014 compared endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus ligation/stripping for saphenous vein varices. (8) Included in the review were 13 randomized studies with a combined total of 3081 patients. The overall quality of the evidence was moderate. There was no significant difference between sclerotherapy and surgery in the rate of recurrence as rated by clinicians (odds ratio [OR], 1.74; p=0.06) or for symptomatic recurrence (OR=1.28). For endovenous laser ablation (EVLA) versus surgery, there were no significant differences between the treatment groups for clinician noted or symptomatic recurrence, or for recanalization. Neovascularization and technical failure were reduced in the laser group (OR=0.05, p<0.001; and OR=0.29, p<0.001, respectively). For endovenous radiofrequency ablation (RFA) versus surgery, there were no significant differences between the groups in clinician noted recurrence, recanalization, neovascularization, or technical failure. The authors concluded that sclerotherapy, EVLA, and RFA are at least as effective as surgery in the treatment of great saphenous varicose veins. In 2014, Brittenden et al. reported a multicenter randomized trial that compared foam sclerotherapy, EVLA, and surgical treatment in 798 patients. (9) The study was funded by U.K. s Health Technology Assessment Programme of the National Institute for Health Research. Veins greater than 15 mm were excluded from the study. At the 6-week follow-up visit, patients who were assigned to treatment with foam or laser had the option of treatment with foam for any residual varicosities; this was performed in 38% of patients in the foam group and 31% of patients in the EVLA group. Six months after treatment, mean disease-specific quality of life was slightly worse after sclerotherapy than after surgery (p=0.006), and there were more residual varicose veins, although the differences were small. Disease-specific quality of life was similar for the laser and surgery groups. The frequency of procedural complications was similar for the foam sclerotherapy (6%) and surgery (7%) groups, but was lower in the laser group (1%). The rate of complications at 6 months (primarily lumpiness and skin staining), was highest for the sclerotherapy group. Endovenous Radiofrequency Ablation (RFA) In 2008, Luebke et al. reported a meta-analysis of 8 studies that included a total of 224 patients who underwent RFA and 204 patients who underwent stripping. (10) There was no significant difference between RFA and surgery in immediate or complete greater saphenous vein occlusion, incomplete greater saphenous vein closure, freedom from reflux, recurrent varicose veins, recanalization, or neovascularization between the 2 treatments. There were significant reductions in tenderness and ecchymosis at 1 week and fewer hematomas at 72 hours, 1

week, and 3 weeks with RFA. Quality-of-life results, including return to normal activity and return to work, favored RFA over surgery. The authors noted that rates of recanalization, retreatment, occlusion, and reflux may alter with longer follow-up and that further RCTs with longer follow-up are needed. Long-term outcomes of endovenous RFA were reported from the Closure Study Group clinical registry in 2005. (11) Thirty-four centers (1,006 patients, 1,222 limbs) participated in the registry, with 12 centers contributing 5- year data (406 limbs). The registry included data on the treatment of 52 lesser saphenous veins and 16 accessory saphenous veins. Follow-up at 1 week showed a 97% anatomic success rate and a decrease in pain in 50% (from 85% to 30%) of patients. An additional 162 failures were identified over the 5 years of follow-up; 129 veins were found to have recanalization, and 33 limbs had reflux in the groin. Logistic regression analysis (risk factors of sex, age, body mass index [BMI]), vein diameter, and catheter pullback speed) showed that BMI was associated with long-term failure. The rate of pull-back speed of the catheter during treatment was associated with failure to occlude or recanalization. Endovenous Laser Ablation (EVLA) The largest trial on EVLA is the 2012 RELACS study, which was a practical design that randomized 400 patients to EVLA performed by a surgeon at 1 site or to ligation and stripping performed by a different surgeon at a second location. (12) At 2-year follow-up, there was no significant difference between the groups for clinically recurrent varicose veins, medical condition on the Homburg Varicose Vein Severity Score, or disease-related quality of life. Saphenofemoral reflux was detected by ultrasonography more frequently after endovenous laser treatment (EVLT) (17.8% vs. 1.3%). This study will follow patients for 5 years. Another trial compared EVLA with ligation and stripping in 200 limbs (100 in each group). (13) At 1-year follow-up, 98% of the limbs were reported to be free of symptoms. At 2-year follow-up, the EVLA group had 2 veins completely reopened and 5 partially reopened, which was significantly greater than in the ligation and stripping group. In the 2013 MAGNA trial, 223 consecutive patients (240 legs) with great saphenous vein reflux were randomized to EVLA, ligation and stripping, or foam sclerotherapy. (14) At 1-year follow-up, the anatomic success rates were similar between EVLA and stripping (88.5% and 88.2%, respectively), which were superior to foam sclerotherapy (72.2%). Ten percent of the stripping group showed neovascularization. Health-related quality of life improved in all groups. The CEAP classification improved in all groups with no significant difference between the groups. Transient adverse events were reported in 11 patients after stripping, 7 after EVLA, and 5 after sclerotherapy. At 5-year follow-up, Kaplan-Meier analysis showed obliteration or absence of the great saphenous vein in 85% of patients who underwent conventional surgery and 77% of patients who underwent EVLA (not significantly different). (15) Grade I neovascularization was higher in the conventional surgery group (27% vs 3%, p<0.001), while grade II neovascularization was similar in the 2 groups (17% vs 13%). Literature on isolated treatment of the anterior accessory saphenous vein is limited. In a 2009 study, outcomes from a cohort of 33 patients who underwent EVLA of the anterior accessory saphenous vein were compared with 33 matched controls undergoing EVLA of the greater saphenous vein. (15) In 21 of the patients (64%) in the accessory saphenous vein group, there had been no previous treatment of the greater saphenous vein. At 12- month follow-up, there was no evidence of reflux in these patients, and the treated accessory saphenous vein was not visible with ultrasound. The Aberdeen Varicose Vein Symptom Severity Score had improved in both groups, with no significant difference between the 2 groups. Patient satisfaction scores were also similar. Sclerotherapy In the 2013 MAGNA trial (previously described), 223 consecutive patients (240 legs) with great saphenous vein reflux were randomized to EVLA, ligation and stripping, or physician compounded foam sclerotherapy (1 cc aethoxysclerol 3%: 3 cc air). (14) At 1-year follow-up, the anatomic success rate of foam sclerotherapy (72.2%) was inferior to both EVLA and stripping (88.5% and 88.2%, respectively). Twenty-one patients in the sclerotherapy group had partial occlusion with reflux, though the clinical complaint was completely relieved. At 5- year follow-up, obliteration or absence of the greater saphenous vein was observed in only 23% of patients treated with sclerotherapy compared to 85% of patients who underwent conventional surgery and 77% of patients who underwent EVLA. (15) Thirty-two percent of legs treated initially with sclerotherapy required 1 or more reinterventions during follow-up compared with 10% in the conventional surgery and EVLA groups. However, clinically relevant grade II neovascularization was higher in the conventional surgery and EVLA groups (17% and 13%, respectively), compared with the sclerotherapy group (4%). EuroQol-5D scores improved equally in all groups. A 2012 study was a noninferiority trial of foam sclerotherapy versus ligation and stripping in 430 patients. (17) Analysis was per protocol. Forty patients (17%) had repeat sclerotherapy. At 2 years, the probability of clinical recurrence was similar in the 2 groups (11.3% sclerotherapy vs. 9.0% ligation and stripping), although

reflux was significantly more frequent in the sclerotherapy group (35% vs. 21%). Thrombophlebitis occurred in 7.4% of patients after sclerotherapy. There were 2 serious adverse events in the sclerotherapy group (deep venous thrombosis and pulmonary emboli) that occurred within 1 week of treatment. In 2013, Varithena microfoam was approved under a new drug application for the treatment of varicose veins. Efficacy data were from 2 randomized, blinded, multicenter studies. (18) One evaluated Varithena at 0.5%, 1.0%, and 2.0% polidocanol and the second evaluated Varithena at 0.5% and 1.0% polidocanol compared with endovenous placebo or a subtherapeutic dose of polidocanol foam. The primary end point was improvement in symptoms at week 8, as measured by the Varicose Vein Symptoms Questionnaire. The improvement in symptoms was greater in the pooled Varithena treatment group (p<0.001) and in each of the individual doseconcentration groups compared with vehicle alone. Secondary and tertiary end points (appearance, duplex ultrasound response, quality of life) were also significantly better for the Varithena groups compared with controls. This second study, called VANISH-2, was published in 2014. (19) At the 8-week assessment, there was elimination of reflux and/or occlusion of the previously incompetent vein in 85.6% of the combined 0.5% and 1.0% groups, 59.6% of patients in the 0.125% group, and 1.8% of the placebo group. Analysis of data from both studies showed a dose response from 0.5% to 2.0% for improvement in appearance and from 0.5% to 1.0% for Duplex responders. The 1.0% dose of Varithena was selected for the FDA approval. Safety analysis found deep vein thrombosis detected by ultrasound in 2.8% of Varithena -treated patients with 1% of patients having proximal symptomatic thrombi; these were treated with anticoagulants. There was no signal of an increase in neurological adverse events, and there were no adverse cardiac or cardiopulmonary effects following treatment with Varithena injectable foam. Rates of occlusion with Varithena are similar to those reported for EVLA or stripping. A randomized trial comparing EVLA and stripping with this new preparation of foam sclerotherapy is needed to evaluate its comparative effectiveness. Evaluation out to 5 years is continuing. Mechanochemical Ablation (MCA) Several prospective series and cohort studies have been reported. One prospective multicenter series evaluated the efficacy of mechanochemical ablation (MCA) of the great saphenous vein in 126 patients in a community setting. (20) Veins were selected that were greater than 4 mm and less than 12 mm in diameter, with an average diameter of 7.3 mm. Closure rates were 100% at 1 week, 98% at 3 months, and 94% at 6 months. The venous clinical severity score decreased from a score of approximately 9 pretreatment to about 3 at 6 months. In 2012, Elias and Raines reported an industry-sponsored safety and efficacy study of MCA with the ClariVein system. (21) Thirty greater saphenous veins in 29 patients were treated with this device. Greater saphenous veins with diameters greater than 12 mm were excluded. At 6-month follow-up, 1 vein had recanalized, for a primary closure rate of 96.7%. No pain during the procedure or adverse events was reported. Another prospective series evaluated MCA of the small saphenous vein in 50 consecutive patients. (22) Only patients with a vein diameter of 2.5 to 11 mm were included. The dose of sclerosant was increased after the first 15 patients. At the 6-week assessment, all treated veins were occluded and at 1-year follow-up, 94% remained occluded. The median visual analog scale score for pain during the procedure was 2 of 10. There were no major complications. Controlled studies with a greater number of subjects and longer follow-up are needed. A 2013 review of MCA notes that a 5-year 840 patient randomized trial comparing ClariVein with RFA began in 2012 in Europe. (23) This trial will provide needed data on the comparative effectiveness of MCA, measured at a longer duration and in a larger population. Early results from this trial (119 patients) indicate that intra-procedural pain is slightly lower with MCA (13.4 mm on a 100-mm scale) compared with RFA (24.4, p=0.001). (24) Cyanoacrylate Adhesion The VenaSeal pivotal study (VeClose) was a multicenter noninferiority trial with 222 patients that compared VenaSeal versus RFA for the treatment of venous reflux. (25, 26) The primary end point, the proportion of patients with complete closure of the target GSV at 3 months measured by ultrasound, was non-inferior to RFA with a 99% closure rate for VenaSeal compared with 96% for RFA. The secondary endpoint of intraoperative pain was similar for the 2 groups (2.2 on a 10-point scale for VenaSeal and 2.4 for RFA, p=0.11). Ecchymosis at day 3 was significantly lower in the cyanoacrylate group; 67.6% of patients treated with cyanoacrylate had no ecchymosis compared with 48.2% of patients following RFA (p<0.01). Scores on the AVVQ and Venous Clinical Severity Score improved to a similar extent in the 2 groups. Longer term follow-up is needed to permit conclusions regarding the durability of this procedure. Twenty-four-month follow-up was reported for 24 of 38 patients enrolled in a study by Almeida et al. (27) Thirtythree month follow-up was reported in 467 veins out of a series of 795 veins (58.7%) treated at 1 institution in

Germany. (28) An inflammatory reddening of the skin was observed at approximately 1 week after treatment in 11.7% of cases. No permanent skin responses were observed. Of the 467 veins re-examined, the sealing rate was 97.7%. This series is limited by the high loss to follow-up. Endovenous Cryoablation Klem et al. reported a randomized trial in 2009 that found endovenous cryoablation (n=249) to be inferior to conventional stripping (n=245) for treating patients with symptomatic varicose veins. (29) The percentage of patients with greater saphenous vein remaining was 44% in the endovenous cryoablation group and 15% in the conventional stripping group. The Aberdeen Varicose Vein Questionnaire also showed better results for conventional stripping (score, 11.7) in comparison with cryoablation (score, 8.0). There were no differences between the groups in SF-36 subscores, and neural damage was the same (12%) in both groups. Disselhoff et al. reported 2 and 5 year outcomes from a randomized trial that compared cryostripping with EVLA. (30, 31) Included were 120 patients with symptomatic uncomplicated varicose veins (CEAP C2) with saphenofemoral incompetence and greater saphenous vein reflux. At 10 days after treatment, EVLA had better results than cryostripping with respect to pain score over the first 10 days (2.9 vs. 4.4), resumption of normal activity (75% vs. 45%) and induration (15% vs. 52%). At 2-year follow-up, freedom from recurrent incompetence was observed in 77% of patients after EVLA and 66% of patients after cryostripping (not significantly different). At 5 years, 36.7% of patients were lost to follow-up; freedom from incompetence and neovascularization was found in 62% of patients treated with EVLA and 51% of patients treated with cryostripping (not significantly different). Neovascularization was more common after cryostripping, but incompetent tributaries were more common after EVLA. There was no significant difference between groups in the Venous Clinical Severity Score or Aberdeen Varicose Vein Severity Score at either 2 or 5 years. Other Treatments Both steam injection and microwave ablation for endovenous treatment of varicose veins were reported outside of the United States. (32-34) These procedures have not been approved or cleared for marketing by FDA. Section Summary: Treatment of Sphenous Reflux There are a number of large randomized trials on endovenous ablation of the saphenous veins. Comparison with ligation and stripping at 2-year follow-up supports use of both RFA and EVLA. Evidence suggests that ligation and stripping may lead to neovascularization, while thermal ablation may lead to recanalization. Controlled studies with longer follow-up are needed to determine the long-term efficacy of these treatments with greater certainty. Two RCTs suggest that cryotherapy is not as effective as available alternatives. For physician-compounded sclerotherapy, there is high variability in success rates of the procedure and reports of serious adverse events. Rates of occlusion with the FDA-approved microfoam sclerotherapy are similar to those reported for EVLA or stripping. MCA is a combination of liquid sclerotherapy with mechanical abrasion. A potential advantage of this procedure compared with thermal ablation techniques is that it does not require tumescent anesthesia and may result in less postoperative pain. To date, the ClariVein procedure has been assessed in relatively few patients and for short durations. Thus, there is insufficient evidence to permit conclusions regarding the safety and efficacy of MCA. Short-term efficacy of cyanoacrylate adhesion has been shown to be noninferior to RF in a large multicenter RCT. Longer term follow-up is needed to determine durability of this treatment. Treatment of Tributary Varicosities Sclerotherapy and Phlebectomy Early studies established ligation and stripping as the criterion standard for the treatment of saphenofemoral incompetence based on improved long-term recurrence rates, with sclerotherapy used primarily as an adjunct to treat varicose tributaries. A 2006 Cochrane Review, based primarily on RCTs from the 1980s, concluded that, The evidence supports the current place of sclerotherapy in modern clinical practice, which is usually limited to treatment of recurrent varicose veins following surgery and thread veins. (35) Sclerotherapy and phlebectomy are considered appropriate in the absence of reflux of the saphenous system, e.g., post- or adjunctive treatment to other procedures such as surgery. (36) In 2014, El-Sheikha et al. reported a small randomized trial of concomitant or sequential (if needed) phlebectomy following EVLA for varicose veins. (37) Quality of life and clinical severity scores were similar between the groups by 1 year, with 16 of 24 patients (67%) in the sequential phlebectomy group receiving a secondary intervention.

A small proportion of patients may present with tributary varicosities in the absence of saphenous reflux. For example, of 1009 patients recruited for an RCT, 64 patients were found to have minor varicose veins without reflux, 34 of whom agreed to be randomized to sclerotherapy or conservative treatment. (38) At baseline, 92% had symptoms of heaviness, 69% had cosmetic concerns, 53% reported itching, and 30% reported relief of symptoms through the use of compression hosiery. At 1-year follow-up, there was an improvement in clinicians assessment of the anatomic extent of varicose veins, with 85% of patients in the sclerotherapy group improved compared with 29% of patients in the conservative-therapy group. Symptoms of aching were better or eliminated in 69% of the sclerotherapy group and 28% of the group treated with conservative therapy. Cosmetic concerns were improved in 85% of the sclerotherapy patients and 14% of controls. The bulk of the literature discussing the role of ultrasound guidance refers to sclerotherapy of the saphenous vein, as opposed to the varicose tributaries. In 2012, Yamaki et al. reported a prospective RCT that compared visual foam sclerotherapy versus ultrasound-guided foam sclerotherapy of the greater saphenous vein together with visual foam sclerotherapy for varicose tributary veins. (39) A total of 51 limbs in 48 patients were treated with ultrasound-guided foam sclerotherapy plus visual foam sclerotherapy of the varicose tributaries, and 52 limbs in 49 patients were treated with foam sclerotherapy alone. At 6-month follow-up, complete occlusion was found in 23 limbs (45.1%) treated with ultrasound-guided and visual-guided foam sclerotherapy and in 22 limbs (42.3%) treated with visual sclerotherapy alone. Reflux was absent in 30 limbs (58.8%) treated with ultrasound and visual guidance and in 37 (71.2%) treated with visual guidance alone (not significantly different). The authors note that for the treatment of tributary veins in clinical practice, most patients receive direct injection of foam without ultrasound guidance. Transilluminated Powered Phlebectomy (TIPP) A 2008 meta-analysis included 5 studies that compared TIPP with conventional surgery. (40) Results showed a significant advantage of TIPP over the conventional treatment for number of incisions, mean cosmetic score, and duration of the procedure. However, TIPP also increased the incidence of hematoma and resulted in worse mean pain scores. Included in the meta-analysis was an RCT by Chetter et al. that compared TIPP (n=29) with a multiple stab incision procedure (n=33). (41) A single surgeon performed all but 2 of the procedures, and there was no difference in operating time. Patients treated with TIPP had an average of 5 incisions, compared with 20 for the multiple stab procedure. However, blinded evaluation revealed that bruising or discoloration was higher for the TIPP group at both 1 and 6 weeks after surgery. At 6 weeks after surgery, patients in the TIPP group showed no improvement in pain (-2 points on the Burford pain scale), while patients in the multiple stab incision group had a significant improvement in pain score compared with presurgical baseline (-20 points). Six weeks after surgery, quality-of-life measures had improved in the multiple-stab incision group but not in the TIPP group. Thus, although TIPP had the advantage of fewer surgical incisions, in this single-center study, it was associated with a more prolonged recovery due to more extensive bruising, prolonged pain, and reduced early postoperative quality of life. The current literature does not show an advantage of TIPP over conventional treatment. Section Summary: Treatment of Tributary Varicosities The literature indicates that sclerotherapy of tributaries following occlusion of the saphenofemoral or saphenopopliteal junction and saphenous veins may be considered medically necessary. Evidence is insufficient to evaluate the health benefit of sclerotherapy as a sole treatment of varicose tributaries without prior or concurrent treatment of the saphenous veins. No studies have been identified that compare RF or laser ablation of tributary veins with standard procedures (microphlebectomy and/or sclerotherapy). Transilluminated powered phlebectomy (TIPP) is effective at removing varicosities; outcomes are comparable with available alternatives such as stab avulsion and hook phlebectomy. However, there is limited evidence that TIPP is associated with more pain, bruising, discoloration, and a longer recovery. Treatment of Perforator Reflux A systematic literature review published in 2008 indicates insufficient evidence for the role of incompetent perforator vein surgery. (5) These conclusions were based on 4 RCTs published since 2000 that compared superficial vein surgery with conservative therapy in advanced chronic venous insufficiency (CEAP category C5 to C6). The 4 trials included 2 level I (large subject population) and 2 level II (small subject population) studies. Two of the trials combined surgical treatment of the incompetent perforator veins with concurrent or prior treatment of the superficial saphenous veins; the other 2 treated the greater saphenous vein alone. The 2 randomized studies in which the greater saphenous vein alone was treated (including the ESCHAR trial) showed a significant

reduction in ulcer recurrence in comparison with conservative therapy. (42, 43) A 2011 community hospital-based multicenter, double-blind, randomized trial found no clinical benefit (self-reported symptoms) from adding subfascial endoscopic perforator surgery (SEPS) to saphenous surgery in 75 patients with varicose ulcers (CEAP C5 or C6) and incompetent perforators. (44) Treatment of the great saphenous vein alone has been reported to improve perforator function. For example, 1 study showed that reversal of perforator vein incompetence (41% of 68 previously incompetent perforators) was more common than new perforator vein incompetence (22% of 183 previously competent perforators) following superficial vein surgery. (45) O Donnell discusses additional (lower quality) evidence to suggest deep venous valvular involvement rather than incompetent perforators in venous insufficiency. (5) Thus, although incompetence of perforator veins is frequently cited as an important etiologic factor in the pathogenesis of venous ulcer, current evidence does not support the routine ligation or ablation of perforator veins. Subfascial Endoscopic Perforator Surgery (SEPS) In 2004, Tenbrook et al. published a review of the literature of SEPS, which included 19 case series and 1 randomized trial. (46) In total, the reviewed studies included 1,031 patients with 1,140 treated limbs. The authors concluded that SEPS was associated with excellent results in terms of ulcer healing and prevention of recurrence. However, the authors also noted that randomized trials are required to define the relative contributions of compression therapy, superficial venous surgery, and SEPS in the management of severe venous disease. In 2015, Van Gent et al reported 10-year follow-up of a randomized trial that compared conservative treatment versus SEPS for venous leg ulcers. (47) Patients (196 legs) returned to the clinic on an annual basis and analysis was conducted with the last-observation carried-forward. The primary outcome, incidence ulcer-free, was significantly higher in the surgical group compared with the conservative treatment group (58.9% vs 39.6%, p=0.007). The number of incompetent perforator veins at follow-up was a risk factor for not being ulcer free (OR=18.5, p<0.001). The relatively high rate of recurrence of the surgically treated group may be due to limited/no stripping of the superficial veins at the time of SEPS. A 2009 meta-analysis of SEPS for chronic venous insufficiency concludes that Its [SEPS] use should not be employed routinely and could only be justified in patients with persistent ulceration thought to be of venous origin, and in whom any superficial reflux has already been ablated and postthrombotic changes excluded. (48) The authors also state that introduction of less invasive techniques for perforator vein ablation, such as ultrasoundguided sclerotherapy or radiofrequency ablation may diminish the role of SEPS in the future." Other Treatments A 2008 review of procedures for management of varicose veins recommends duplex-guided foam sclerotherapy, microincision phlebectomy, or thermal ablation using a new short RFA catheter for the treatment of symptomatic residual perforator vein incompetence. (49) Ablation of incompetent perforator veins with laser or RFA had been shown to be technically feasible, although no studies had been identified that showed an improvement in clinical outcomes (e.g., ulcer healing or recurrence). The 2011 literature update identified 1 study of EVLA for perforating veins in 33 patients with a CEAP classification of 4 (skin changes), 5 (healed ulcer), or 6 (active ulcer). (50) All incompetent saphenous trunks were treated simultaneously (63% of limbs). At 3-month follow-up, occlusion was achieved in 78% of the perforating veins. Five patients (15%) had active ulcers at baseline; 4 of the 5 ulcers had healed by 6 weeks after EVLA. Evidence regarding the treatment of perforator veins with ultrasound-guided sclerotherapy is limited, and there is a risk of deep venous occlusion. (51) Summary of Evidence: Treatment of Perforator Reflux Although randomized controlled trials (RCTs) with longer follow-up are needed to evaluate long-term durability, and repeat treatments may be required, evidence indicates that endovenous treatment of saphenous veins with radiofrequency or laser ablation improves short-term clinical outcomes (e.g., pain and return to work) in comparison with surgery. Ultrasound-guided foam sclerotherapy (physician compounded) leads to success rates that approach that of surgery. There are no trials comparing the recently U.S. Food and Drug Administration (FDA).approved microfoam sclerotherapy with other treatments of varicose veins. Results from a recent RCT of cryoablation indicate that this therapy is inferior to conventional stripping. There is insufficient evidence on mechanochemical ablation. The literature indicates that sclerotherapy of tributaries following occlusion of the saphenofemoral or saphenopopliteal junction and saphenous veins may be considered medically necessary. Evidence is insufficient

to evaluate the health benefit of sclerotherapy as a sole treatment of varicose tributaries without prior or concurrent treatment of the saphenous veins. No studies have been identified that compare radiofrequency or laser ablation of tributary veins with standard procedures (microphlebectomy and/or sclerotherapy). Transilluminated powered phlebectomy is effective at removing varicosities; outcomes are comparable with available alternatives such as stab avulsion and hook phlebectomy. The literature indicates that the routine ligation/ablation of incompetent perforator veins is not medically necessary for the treatment of varicose veins/venous insufficiency at the time of superficial vein procedures. However, when combined, superficial vein procedures and compression therapy have failed to improve symptoms (i.e., ulcers); treatment of perforator vein reflux may be as beneficial as any alternative (e.g., deep vein valve replacement). Therefore, treatment of incompetent perforator veins may be considered medically necessary in this specific situation. Comparative studies are needed to determine the most effective method of ligating/ablating incompetent perforator veins. SEPS has been shown to be as effective as the Linton procedure with a reduction in adverse events. Although only 1 case series has been identified showing an improvement in health outcomes, endovenous ablation with specialized laser or radiofrequency probes has been shown to effectively ablate incompetent perforator veins with a potential decrease in morbidity in comparison with surgical interventions. For sclerotherapy, concerns have been raised about the risk of deep vein occlusion, and evidence is currently insufficient to evaluate the safety or efficacy of this treatment for incompetent perforator veins. Ongoing and Unpublished Clinical Trials Some currently unpublished trials that might influence this policy are listed in Table 1. Table 1. Summary of Key Trials NCT No. Trial Name Planned Enrollment Ongoing NCT01807585 a NCT 01459263 NTR4613 a Randomized Control Trial Comparing VenaSeal Sapheon Closure System With Radiofrequency Ablation (Pivotal Study) Mechanochemical Endovenous Ablation of Great Saphenous Vein Incompetence Using the ClariVein Device: a Prospective Study Mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary small saphenous vein insufficiency (MESSI trial) NCT: national clinical trial. NTR: Netherlands Trial Registry. a Denotes industry-sponsored or cosponsored trial. Completion Date 244 Sep 2016 100 Dec 2017 160 Apr 2020 Summary of Evidence The evidence on mechanochemical ablation, cyanoacrylate adhesive, and cryoablation in patients with varicose veins/venous insufficiency includes randomized controlled trials (RCTs) and multicenter series. Relevant outcomes are symptoms, morbid events, functional outcomes, and change in disease status. Several series have been reported on mechanochemical ablation (MCA), and a large RCT comparing MCA with radiofrequency RF ablation is ongoing. Efficacy of cyanoacrylate adhesion at 3 months has been shown to be noninferior to RF in a multicenter RCT. Longer term follow-up is needed to determine durability of this treatment. Results from a recent RCT of cryoablation indicate that this therapy is inferior to conventional stripping. The evidence is insufficient to determine the effects of the technology on health outcomes. Practice Guidelines and Position Statements The Society for Vascular Surgery and the American Venous Forum (AVF)

The Society for Vascular Surgery and the American Venous Forum (AVF) published clinical practice guidelines in 2011. (46) The recommendations are rated as strong = 1 or weak = 2, based on a level of evidence that is either high quality = A, moderate quality = B, or low quality = C, and include the following: Compression therapy for venous ulcerations and varicose veins: Compression therapy is recommended as the primary treatment to aid healing of venous ulceration (GRADE 1B, strong recommendation, moderate quality evidence). To decrease the recurrence of venous ulcers, they recommend ablation of the incompetent superficial veins in addition to compression therapy (GRADE 1A, strong recommendation, high quality evidence). They recommend use of compression therapy for patients with symptomatic varicose veins (GRADE 2C, weak recommendation, low-quality evidence) but recommend against compression therapy as the primary treatment if the patient is a candidate for saphenous vein ablation (GRADE 1B, strong recommendation, moderate quality evidence). Treatment of the incompetent great saphenous vein: Endovenous thermal ablation (radiofrequency or laser) is recommended over chemical ablation with foam (GRADE 1B, strong recommendation, moderate quality evidence) or high ligation and stripping (GRADE 1B, strong recommendation, moderate quality evidence) due to reduced convalescence and less pain and morbidity. Cryostripping is a technique that is new in the United States, and it has not been fully evaluated. Varicose tributaries: Phlebectomy or sclerotherapy are recommended to treat varicose tributaries (GRADE 1B, strong recommendation, moderate quality evidence). Transilluminated powered phlebectomy using lower oscillation speeds and extended tumescence is an alternative to traditional phlebectomy (GRADE 2C, weak recommendation, low quality evidence). Perforating vein incompetence: Selective treatment of perforating vein incompetence in patients with simple varicose veins is not recommended (CEAP class C2; GRADE 1B, strong recommendation, moderate quality evidence), but there is a GRADE 2B recommendation (weak recommendation, moderate quality evidence) for treatment of pathologic perforating veins (outward flow of > 500 ms duration, with a diameter of > 3.5 mm) located underneath healed or active ulcers (CEAP class C5-C6) by subfascial endoscopic perforating vein surgery, sclerotherapy, or thermal ablations (GRADE 1C, weak recommendation, low quality evidence). American College of Radiology (ACR) In 2012 the American College of Radiology published their latest version of appropriateness criteria for the treatment of lower-extremity venous insufficiency. (52) The following is a summary of treatment options: Compression Stockings: Graduated compression stockings are routinely used to control venous insufficiency symptoms. They provide external support that can constrict dilated veins and restore competence to incompetent valves. Compression stockings are particularly helpful during pregnancy, and they are frequently used following venous ablation treatment. Surgery: Great saphenous vein (GSV) stripping with branch ligation had historically been the primary treatment option for venous insufficiency. The GSV is ligated near the groin. Ligation alone can preserve the vein for subsequent harvesting in case of arterial bypass; however, ligation alone has proven unsatisfactory for preventing the occurrence of reflux, so it is often supplemented by vein stripping. Ambulatory phlebectomy is primarily used to treat surface varicose veins. It can be performed as an adjunct to endovenous ablation or stripping. This procedure involves making tiny punctures or incisions through which the varicose veins are removed. Other surgical methods to treat venous insufficiency have been described, including SEPS for treating venous ulcers and valvular surgery for treating reflux caused by incompetent valves of the deep veins. Injection Sclerotherapy: Injection sclerotherapy is a common treatment for telangiectasias and can be used to treat smaller varicose veins. The sclerotherapy solution can be in liquid form or can be injected as "foam" (mixed with a gas such as air). Sclerotherapy has not been shown to have long-term effectiveness for large veins, such as the GSV. Endovenous Ablation: Endovenous ablation is a minimally invasive alternative to surgery. It is a percutaneous procedure that can be used to treat the GSV, small saphenous vein (SSV), and other superficial veins. Endovenous ablation uses RFA or laser energy (EVLA) applied inside the vein to cause occlusion. Small prospective trials comparing EVLA and RFA with conventional surgery in patients with GSV reflux have shown favorable results. One study demonstrated that EVLA is comparable to surgery in abolishing reflux and improving disease-specific quality of life and that it allows earlier return to normal activity. A recent systematic literature review comparing the safety and efficacy of EVLA and surgery involving saphenous ligation and stripping as treatments for varicose veins showed few differences in clinical effectiveness outcomes, although long-term follow-up was lacking. A meta-analysis suggested that EVLA and RFA are at least as effective as surgery in treating lower-extremity varicose veins. After 3 years, the estimated pooled success rates for treatment were 78% for surgical stripping, 77% for foam

sclerotherapy, 84% for RFA, and 94% for laser therapy. Adjunctive Treatments: Adjunctive treatments may be required to help eliminate venous insufficiency. Patients with venous insufficiency and associated venous occlusion or stenosis of the common iliac vein (e.g., May-Thurner syndrome) may require venous recanalization with angioplasty and stenting to achieve a patent conduit for venous return. Patients with pelvic venous insufficiency may require percutaneous embolization of the ovarian veins. Patients with deep venous thrombosis are typically treated with anticoagulation to reduce the risk of thrombus propagation, embolization, and postthrombotic syndrome. One study suggested that endovenous ablation of the saphenous vein can be considered as a viable treatment alternative in patients with venous insufficiency and previous deep venous thrombosis. Complications: All forms of lower-extremity venous insufficiency treatment are subject to recurrence. Additional risks of vein ligation and stripping surgery include: anesthetic risk, scarring, pain, bleeding, deep venous injury or thrombosis, nerve injury, and infection. Complications of the endovenous ablation procedure include bruising, swelling, transient numbness, and rarely deep venous thrombosis. Society of Interventional Radiography (SIR) In 2003, the Society of Interventional Radiography (SIR) published a position statement (53) that considered endovenous ablation therapy, using either laser or radiofrequency devices under imaging guidance and monitoring, an effective treatment of extremity venous reflux and varicose veins under the following conditions: 1. The endovenous treatment of varicose veins may be medically necessary when one of the following indications (a - e) is present: a. Persistent symptoms interfering with activities of daily living in spite of conservative/nonsurgical management. Symptoms include aching, cramping, burning, itching, and/or swelling during activity or after prolonged standing. b. Significant recurrent attacks of superficial phlebitis c. Hemorrhage from a ruptured varix d. Ulceration from venous stasis where incompetent varices are a contributing factor e. Symptomatic incompetence of the great or small saphenous veins (symptoms as in a above); and 2. A trial of conservative, nonoperative treatment has failed. This would include mild exercise, avoidance of prolonged immobility, periodic elevation of legs, and compressive stockings; and 3. The patient's anatomy is amenable to endovenous ablation. In a joint statement published in 2007, AVF and SIR recommended reporting standards for endovenous ablation for the treatment of venous insufficiency. (55) The document recommended that reporting in clinical studies should include the symptoms of venous disease, history of disease and prior treatment, the presence of major comorbidities, and any exclusion criteria. It was noted that potential candidates for endovenous ablation may include patients with reflux in an incompetent greater saphenous vein or smaller saphenous vein or in a major tributary branch of the greater or smaller saphenous veins such as the anterior thigh circumflex vein, posterior thigh circumflex vein, or anterior accessory greater saphenous vein. The presence of reflux in these veins is important to document using duplex ultrasound imaging, and the ultrasound criteria used to define reflux should be indicated. It was also stated that in current practice, most vascular laboratories consider the presence of venous flow reversal for greater than 0.5 to 1.0 second with proximal compression, Valsalva maneuver, or distal compression and release to represent pathologic reflux. National Institute for Health and Care Excellence (NICE) In 2003 and 2004, the U.K. s National Institute for Health and Care Excellence (NICE) published guidance on radiofrequency ablation of varicose veins and on endovenous laser treatment of the long saphenous vein. (56, 57) NICE concluded that the evidence on the safety and efficacy appeared adequate to support the use of these procedures provided that the normal arrangements were in place for consent, audit, and clinical governance. The evidence on efficacy at this time was limited to case series with limited follow-up. Clinicians were encouraged to collect longer-term follow up data. NICE issued updated guidance on ultrasound-guided foam sclerotherapy for varicose veins in 2013. (58) The guidance states that: 1.1 Current evidence on the efficacy of ultrasound-guided foam sclerotherapy for varicose veins is adequate. The evidence on safety is adequate, and provided that patients are warned of the small but significant risks of foam embolization (see section 1.2), this procedure may be used with normal

arrangements for clinical governance, consent and audit. 1.2 During the consent process, clinicians should inform patients that there are reports of temporary chest tightness, dry cough, headaches and visual disturbance, and rare but significant complications including myocardial infarction, seizures, transient ischaemic attacks and stroke. NICE issued guidance on endovenous mechanochemical ablation in 2013, concluding that current evidence on the safety and efficacy of endovenous mechanochemical ablation for varicose veins is inadequate in quantity and quality. (59) Therefore this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. In 2013, NICE published practice guideline on the diagnosis and management of varicose veins in the leg. (60) NICE recommends a study of the clinical and cost effectiveness of Concurrent phlebectomies or foam sclerotherapy for varicose tributaries during truncal endothermal ablation for varicose veins Truncal endothermal ablation without concurrent phlebectomies or foam sclerotherapy Truncal endothermal ablation with phlebectomies or foam sclerotherapy, if needed, 6-12 weeks later. In 2015, NICE published a technology assessment on the clinical effectiveness and cost-effectiveness of foam sclerotherapy, endovenous laser ablation, and surgery for varicose veins. (61) Cost-effectiveness was based on a large multicenter randomized trial comparing treatments for varicose veins (described previously). (9) Five-year trial results are currently being evaluated. U.S. Preventive Services Task Force Recommendations Not applicable. Medicare National Coverage There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers. References [TOP] 1. O'Meara S, Cullum NA, Nelson EA. Compression for venous leg ulcers. Cochrane Database Syst Rev 2009; (1):CD000265. PMID 19160178 2. O'Meara S, Cullum N, Nelson EA, et al. Compression for venous leg ulcers. Cochrane Database Syst Rev. 2012;11:CD000265. PMID 23152202 3. Shingler S, Robertson L, Boghossian S et al. Compression stockings for the initial treatment of varicose veins in patients without venous ulceration. Cochrane Database Syst Rev 2011; 11:CD008819. PMID 23152202 4. Howard DP, Howard A, Kothari A et al. The role of superficial venous surgery in the management of venous ulcers: a systematic review. Eur J Vasc Endovasc Surg 2008; 36(4):458-65. PMID 18675558 5. O'Donnell TF, Jr. The present status of surgery of the superficial venous system in the management of venous ulcer and the evidence for the role of perforator interruption. J Vasc Surg 2008; 48(4):1044-52. PMID 18992425 6. Jones L, Braithwaite BD, Selwyn D et al. Neovascularisation is the principal cause of varicose vein recurrence: results of a randomised trial of stripping the long saphenous vein. Eur J Vasc Endovasc Surg 1996; 12(4):442-5. PMID 8980434 7. Rutgers PH, Kitslaar PJ. Randomized trial of stripping versus high ligation combined with sclerotherapy in the treatment of the incompetent greater saphenous vein. Am J Surg 1994; 168(4):311-5. PMID 7943585 8. Nesbitt C, Eifell RK, Coyne P et al. Endovenous ablation (radiofrequency and laser) and foam sclerotherapy versus conventional surgery for great saphenous vein varices. Cochrane Database Syst Rev 2011; (10):CD005624. PMID 25075589 9. Brittenden J, Cotton SC, Elders A, et al. A randomized trial comparing treatments for varicose veins. N Engl J Med. Sep 25 2014;371(13):1218-1227. PMID 25251616 10. Luebke T, Gawenda M, Heckenkamp J et al. Meta-analysis of endovenous radiofrequency obliteration of

the great saphenous vein in primary varicosis. J Endovasc Ther 2008; 15(2):213-23. PMID 18426271 11. Merchant RF, Pichot O. Long-term outcomes of endovenous radiofrequency obliteration of saphenous reflux as a treatment for superficial venous insufficiency. J Vasc Surg 2005; 42(3):502-9; discussion 509. PMID 16171596 12. Rass K, Frings N, Glowacki P, et al. Comparable effectiveness of endovenous laser ablation and high ligation with stripping of the great saphenous vein: two-year results of a randomized clinical trial (RELACS study). Arch Dermatol. Jan 2012;148(1):49-58. PMID 21931012 13. Christenson JT, Gueddi S, Gemayel G, et al. Prospective randomized trial comparing endovenous laser ablation and surgery for treatment of primary great saphenous varicose veins with a 2-year follow-up. J Vasc Surg. Nov 2010;52(5):1234-1241. PMID 20801608 14. Biemans AA, Kockaert M, Akkersdijk GP, et al. Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins. J Vasc Surg. Sep 2013;58(3):727-734 e721. PMID 23769603 15. van der Velden SK, Biemans AA, De Maeseneer MG, et al. Five-year results of a randomized clinical trial of conventional surgery, endovenous laser ablation and ultrasound-guided foam sclerotherapy in patients with great saphenous varicose veins. Br J Surg. Jul 1 2015. PMID 26132315 16. Theivacumar NS, Darwood R, Gough MJ. Endovenous laser ablation (EVLA) of the anterior accessory great saphenous vein (AAGSV): abolition of sapheno-femoral reflux with preservation of the great saphenous vein. Eur J Vasc Endovasc Surg. Apr 2009;37(4):477-481. PMID 19201621 17. Shadid N, Ceulen R, Nelemans P, et al. Randomized clinical trial of ultrasound-guided foam sclerotherapy versus surgery for the incompetent great saphenous vein. Br J Surg. Aug 2012;99(8):1062-1070. PMID 22627969 18. U.S. Food and Drug Administration Center for Drug Evaluation and Research. 205098 Varithena Summary Review. 2013; http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/205098orig1s000sumr.pdf. Accessed December, 2015. 19. Todd KL, 3rd, Wright D, for the V-IG. The VANISH-2 study: a randomized, blinded, multicenter study to evaluate the efficacy and safety of polidocanol endovenous microfoam 0.5% and 1.0% compared with placebo for the treatment of saphenofemoral junction incompetence. Phlebology. Oct 2014;29(9):608-618. PMID 23864535 20. Bishawi M, Bernstein R, Boter M, et al. Mechanochemical ablation in patients with chronic venous disease: A prospective multicenter report. Phlebology. Jul 2 2013. PMID 23820117 21. Elias S, Raines JK. Mechanochemical tumescentless endovenous ablation: final results of the initial clinical trial. Phlebology. Mar 2012;27(2):67-72. PMID 21803800 22. Boersma D, van Eekeren RR, Werson DA, et al. Mechanochemical endovenous ablation of small saphenous vein insufficiency using the ClariVein((R)) device: one-year results of a prospective series. Eur J Vasc Endovasc Surg. Mar 2013;45(3):299-303. PMID 23312507 23. Mueller RL, Raines JK. ClariVein mechanochemical ablation: background and procedural details. Vasc Endovascular Surg. Apr 2013;47(3):195-206. PMID 23509062 24. Bootun R, Lane T, Dharmarajah B, et al. Intra-procedural pain score in a randomised controlled trial comparing mechanochemical ablation to radiofrequency ablation: The Multicentre Venefit versus ClariVein(R) for varicose veins trial. Phlebology. Sep 5 2014. PMID 25193822 25. U.S. Food and Drug Administration. VenaSeal Closure System - P140018. 2015; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p140018. Accessed December, 2015 26. Morrison N, Gibson K, McEnroe S, et al. Randomized trial comparing cyanoacrylate embolization and radiofrequency ablation for incompetent great saphenous veins (VeClose). J Vasc Surg. Apr 2015;61(4):985-994. PMID 25650040 27. Almeida JI, Javier JJ, Mackay EG, et al. Two-year follow-up of first human use of cyanoacrylate adhesive for treatment of saphenous vein incompetence. Phlebology. Jul 2015;30 (6):397-404. PMID 24789750 28. Zierau U. Sealing Veins with the VenaSeal Sapheon Closure System: Results for 795 Treated Truncal Veins after 1000 Days. Vasomed. 2015;27:124-127. 29. Klem TM, Schnater JM, Schutte PR et al. A randomized trial of cryo stripping versus conventional stripping of the great saphenous vein. J Vasc Surg 2009; 49(2):403-409. PMID 19028042 30. Disselhoff BC, der Kinderen DJ, Kelder JC et al. Randomized clinical trial comparing endovenous laser with cryostripping for great saphenous varicose veins. Br J Surg 2008; 95(10):1232-1238. PMID 18763255 31. Disselhoff BC, der Kinderen DJ, Kelder JC et al. Five-year results of a randomized clinical trial comparing endovenous laser ablation with cryostripping for great saphenous varicose veins. Br J Surg 2011; 98(8):1107-1111. PMID 21633948

32. Milleret R, Huot L, Nicolini P, et al. Great saphenous vein ablation with steam injection: results of a multicenter study. Eur J Vasc Endovasc Surg. Apr 2013;45(4):391-396. PMID 23410966 33. Yang L, Wang XP, Su WJ, et al. Randomized clinical trial of endovenous microwave ablation combined with high ligation versus conventional surgery for varicose veins. Eur J Vasc Endovasc Surg. Oct 2013;46(4):473-479. PMID 23911734 34. van den Bos RR, Malskat WS, De Maeseneer MG, et al. Randomized clinical trial of endovenous laser ablation versus steam ablation (LAST trial) for great saphenous varicose veins. Br J Surg. Aug 2014;101(9):1077-1083. PMID 24981585 35. Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database Syst Rev 2006; (4):CD001732. PMID 17054141 36. Leopardi D, Hoggan BL, Fitridge RA, et al. Systematic review of treatments for varicose veins. Ann Vasc Surg. Mar 2009;23(2):264-276. PMID 19059756 37. El-Sheikha J, Nandhra S, Carradice D, et al. Clinical outcomes and quality of life 5 years after a randomized trial of concomitant or sequential phlebectomy following endovenous laser ablation for varicose veins. Br J Surg. Aug 2014;101(9):1093-1097. PMID 24916467 38. Michaels JA, Campbell WB, Brazier JE et al. Randomised clinical trial, observational study and assessment of cost-effectiveness of the treatment of varicose veins (REACTIV trial). Health Technol Assess 2006; 10(13):1-196, iii-iv. PMID 16707070 39. Yamaki T, Hamahata A, Soejima K et al. Prospective Randomised Comparative Study of Visual Foam Sclerotherapy Alone or in Combination with Ultrasound-guided Foam Sclerotherapy for Treatment of Superficial Venous Insufficiency: Preliminary Report. Eur J Vasc Endovasc Surg 2012. PMID 22230599 40. Luebke T, Brunkwall J. Meta-analysis of transilluminated powered phlebectomy for superficial varicosities. J Cardiovasc Surg (Torino) 2008; 49(6):757-764. PMID 19043390 41. Chetter IC, Mylankal KJ, Hughes H et al. Randomized clinical trial comparing multiple stab incision phlebectomy and transilluminated powered phlebectomy for varicose veins. Br J Surg 2006; 93(2):169-174. PMID 16432820 42. Barwell JR, Davies CE, Deacon J et al. Comparison of surgery and compression with compression alone in chronic venous ulceration (ESCHAR study): randomised controlled trial. Lancet 2004; 363(9424):1854-1859. PMID 15183623 43. Gohel MS, Barwell JR, Taylor M et al. Long term results of compression therapy alone versus compression plus surgery in chronic venous ulceration (ESCHAR): randomised controlled trial. BMJ 2007; 335(7610):83. PMID 17545185 44. Nelzen O, Fransson I. Early results from a randomized trial of saphenous surgery with or without subfascial endoscopic perforator surgery in patients with a venous ulcer. Br J Surg 2011; 98(4):495-500. PMID 21656715 45. Blomgren L, Johansson G, Dahlberg-Akerman A et al. Changes in superficial and perforating vein reflux after varicose vein surgery. J Vasc Surg 2005; 42(2):315-320. PMID 16102633 46. Tenbrook JA, Jr., Iafrati MD, O'Donnell T F, Jr. et al. Systematic review of outcomes after surgical management of venous disease incorporating subfascial endoscopic perforator surgery. J Vasc Surg 2004; 39(3):583-589. PMID 14981453 47. van Gent WB, Catarinella FS, Lam YL, et al. Conservative versus surgical treatment of venous leg ulcers: 10-year follow up of a randomized, multicenter trial. Phlebology. Mar 2015;30(1 Suppl):35-41. PMID 25729066 48. Luebke T, Brunkwall J. Meta-analysis of subfascial endoscopic perforator vein surgery (SEPS) for chronic venous insufficiency. Phlebology 2009; 24(1):8-16. PMID 19155335 49. Hirsch SA, Dillavou E. Options in the management of varicose veins, 2008. J Cardiovasc Surg (Torino) 2008; 49(1):19-26. PMID 18212684 50. Hissink RJ, Bruins RM, Erkens R et al. Innovative treatments in chronic venous insufficiency: endovenous laser ablation of perforating veins: a prospective short-term analysis of 58 cases. Eur J Vasc Endovasc Surg 2010; 40(3):403-406. PMID 20547462 51. Myers KA, Jolley D. Factors affecting the risk of deep venous occlusion after ultrasound-guided sclerotherapy for varicose veins. Eur J Vasc Endovasc Surg. Nov 2008;36(5):602-605. PMID 18718772 52. Gloviczki P, Comerota AJ, Dalsing MC et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg 2011; 53(5 Suppl):2S-48S. PMID 21536172 53. Silberzweig JE, Funaki BS, Ray CE, Jr. et al. ACR appropriateness criteria treatment of lower-extremity venous insufficiency. 2013. Available online at: http://www.guideline.gov/content.aspx?id=43869. Accessed December, 2015. 54. Society of Interventional Radiology. Position Statement on Endovenous Ablation. 2003. Available online at: http://www.sirweb.org/clinical/cpg/sir_venous_ablation_statement_final_dec03.pdf. Accessed